If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

I am interested in the development of new agents and treatment approaches for patients with myelodysplastic syndromes and acute myeloid leukemia. In conjunction with Drs. John DiPersio and Michael Rettig, we are currently conducting a Phase I/II Study of AMD3100 (plerixafor) in combination with mitoxantrone, etoposide and cytarabine for relapsed or refractory AML. AMD3100 is a CXCR4 antagonist currently under clinical development as a stem cell mobilizing agent for use in hematopoietic transplantation. Preclinical evidence suggests that AMD3100 can disrupt the interaction of leukemic blasts with the bone marrow microenvironment sensitizing these cells to genotoxic stresses such as chemotherapy. This trial is designed as a proof of concept study to determine if AMD3100 "priming" can improve response rates in AML.

Areas of Clinical Interest

Bone marrow transplant, oncology, cancer, lymphoma, leukemia, aplastic anemia

Fingerprint Dive into the research topics where Geoffrey Uy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 39 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

All I really need to know I learned from pediatric oncologists

Uy, G. L., May 1 2020, In : JCO Oncology Practice. 16, 5, p. 239-240 2 p.

Research output: Contribution to journalComment/debate

Clinical and functional significance of circular RNAs in cytogenetically normal AML

Papaioannou, D., Volinia, S., Nicolet, D., Świerniak, M., Petri, A., Mrózek, K., Bill, M., Pepe, F., Walker, C. J., Walker, A. E., Carroll, A. J., Kohlschmidt, J., Eisfeld, A. K., Powell, B. L., Uy, G. L., Kolitz, J. E., Wang, E. S., Kauppinen, S., Dorrance, A., Stone, R. M. & 3 others, Byrd, J. C., Bloomfield, C. D. & Garzon, R., Jan 28 2020, In : Blood Advances. 4, 2, p. 239-251 13 p.

Research output: Contribution to journalArticle

Open Access
  • 1 Scopus citations

    Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

    Marcucci, G., Geyer, S., Laumann, K., Zhao, W., Bucci, D., Uy, G. L., Blum, W., Eisfeld, A. K., Pardee, T. S., Wang, E. S., Stock, W., Kolitz, J. E., Kohlschmidt, J., Mrózek, K., Bloomfield, C. D., Stone, R. M. & Larson, R. A., Feb 25 2020, In : Blood Advances. 4, 4, p. 696-705 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

    Klepin, H. D., Ritchie, E., Major-Elechi, B., Le-Rademacher, J., Seisler, D., Storrick, L., Sanford, B. L., Marcucci, G., Zhao, W., Geyer, S. A., Ballman, K. V., Powell, B. L., Baer, M. R., Stock, W., Cohen, H. J., Stone, R. M., Larson, R. A. & Uy, G. L., Jan 2020, In : Journal of Geriatric Oncology. 11, 1, p. 107-113 7 p.

    Research output: Contribution to journalArticle

  • 4 Scopus citations

    Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

    Roboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T., Altman, J. K., Arellano, M. L., Donnellan, W., Erba, H. P., Mannis, G. N., Pollyea, D. A., Stein, A. S., Uy, G. L., Watts, J. M., Fathi, A. T., Kantarjian, H. M., Tallman, M. S., Choe, S., Dai, D. & 11 others, Fan, B., Wang, H., Zhang, V., Yen, K. E., Kapsalis, S. M., Hickman, D., Liu, H., Agresta, S. V., Wu, B., Attar, E. C. & Stone, R. M., Feb 13 2020, In : Blood. 135, 7, p. 463-471 9 p.

    Research output: Contribution to journalReview article

    Open Access
  • 16 Scopus citations